Last reviewed · How we verify
Cohort HIVOL, patients infected by HIV — Competitive Intelligence Brief
marketed
Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Cohort HIVOL, patients infected by HIV (Cohort HIVOL, patients infected by HIV) — Centre Hospitalier Universitaire de Saint Etienne. Cohort HIVOL is a clinical cohort study monitoring HIV-infected patients, not a drug with a specific mechanism of action.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cohort HIVOL, patients infected by HIV TARGET | Cohort HIVOL, patients infected by HIV | Centre Hospitalier Universitaire de Saint Etienne | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cohort HIVOL, patients infected by HIV CI watch — RSS
- Cohort HIVOL, patients infected by HIV CI watch — Atom
- Cohort HIVOL, patients infected by HIV CI watch — JSON
- Cohort HIVOL, patients infected by HIV alone — RSS
Cite this brief
Drug Landscape (2026). Cohort HIVOL, patients infected by HIV — Competitive Intelligence Brief. https://druglandscape.com/ci/cohort-hivol-patients-infected-by-hiv. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab